Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Oppenheimer Is Confident in Walmart's Value Strategy After Tariff Chaos, Here's the Specific Business Advantage That Keeps WMT Winning

Walmart's capability to navigate tariff chaos is unmatched in the retail sector. The company maintains over 11,000 supplier relationships, allowing it to shift sourcing across more than 60 countries within a remarkably short timeframe of 60 to 90 days. This flexibility provides Walmart with …

Nitish Kishor | 09 June 2026

4 Trillion-Dollar Companies Are Genius Buys Right Now, Here's the Specific Valuation Case for Owning All Four at Once

As theInvestmentlandscape evolves, four U.S. corporations, each exceeding a $1 trillion market cap, present a compelling case forAcquisition. Apple Inc. (Nasdaq: AAPL), Alphabet Inc. (NASDAQ: GOOGL), Amazon.com Inc. (NASDAQ: AMZN), and Meta Platforms Inc. (NASDAQ: META) not only display individual merit but collectively form …

Nitish Kishor | 09 June 2026

Exxon's CEO Gave the Most Honest Oil Price Assessment on Wall Street, Here's the Data Behind His Blunt Warning

In an unusual display of transparency, Darren Woods, CEO of ExxonMobil (NYSE: XOM), recently addressed the volatile landscape of oil pricing. While he refrained from forecasting exact price levels, Woods revealed that ExxonMobil’s financial strategies are robust enough to withstand scenarios where oil prices …

Nitish Kishor | 09 June 2026

Is Altimmune Worth Buying Before Its 2026 Catalysts? Here's Whether This GLP-1 Challenger Can Compete With Eli Lilly

Altimmune (Nasdaq: ALT) is positioning itself in a competitive landscape with its development of pemvidutide, a GLP-1/glucagon dual agonist. Early data from Phase 2 trials suggest that pemvidutide can achieve weight loss exceeding 15% over 48 weeks, with a notable reduction in muscle loss …

Nitish Kishor | 09 June 2026

The $30 Trillion Space Dream

Ron Baron, the astute growth investor renowned for his substantial returns on Tesla, has put forth a startling projection for SpaceX: a valuation of $30 trillion. This figure, equivalent to the combined market capitalisations of Apple, Microsoft, NVIDIA, and Google, is not mere hyperbole. …

Nitish Kishor | 09 June 2026

Is Exxon Worth Its Premium Price? Here's the Sum-of-Parts Valuation That Reveals Whether XOM Is Cheap or Expensive at $120 Oil

ExxonMobil (NYSE: XOM) presents an intriguingInvestmentcase, particularly at a time when oil prices hover around $120 per barrel. A detailed sum-of-parts analysis reveals that Exxon’s operations, spanning the lucrative Permian Basin, deepwater projects in Guyana, and integration synergies from itsAcquisitionof Pioneer Natural Resources, collectivelyYieldan …

Nitish Kishor | 09 June 2026

Cathie Wood Put a $75 Robotaxi Value Into Tesla's Bull Case, Here's Whether the $2,600 Price Target Is Genius or Delusional

Cathie Wood's ARK Invest has generated considerable buzz with its $2,600 price target for Tesla (Nasdaq: TSLA), predicated on the potential of a robotaxi network. This target includes a significant $75 per share derived from expected revenues generated by 1.5 million robotaxis, each running …

Nitish Kishor | 09 June 2026

Apple's Slow AI Bet Is Starting to Look Very Smart, Here's the Privacy Moat That Google and Microsoft Are Structurally Incapable of Replicating

Apple Inc. (Nasdaq: AAPL) has long been criticized for its seemingly cautious approach to artificial intelligence, especially when compared to the rapid advancements of competitors like Google and Microsoft. However, this "slow and steady" strategy is beginning to reveal its merit. Central to Apple's …

Nitish Kishor | 09 June 2026

Forget JEPI, These 3 BDC ETFs Yield 12%+ From Private Credit, Here's the Honest Sustainability Analysis Every Income Investor Must Read

The landscape of fixed-income investment is rapidly shifting, with traditional avenues likeGovernment Bondsand corporateDebtyieldingDiminishing Returns. In this context, Business Development Companies (BDCs) have emerged as attractive alternatives. ETFs such as PBDC and BIZD focus on private credit, a sector that has quietly ballooned to …

Nitish Kishor | 09 June 2026

Goldman Sachs Kept Abbott Laboratories at Buy, Here's the Medical Device Growth Engine That the Market Is Systematically Undervaluing

Goldman Sachs' endorsement of Abbott Laboratories hinges on the impressive trajectory of its FreeStyle Libre continuous glucose monitoring (CGM) franchise. With annual revenues exceeding $6 billion and a growth rate surpassing 20%, thisBusinesssegment represents a formidable growth engine amid large-cap healthcare companies. The expansion …

Nitish Kishor | 09 June 2026
Support

Hi! How can we help you today?

Loading…